A canine model with cyclic flow variations (CFVs) in stenosed and endothelium-injured coronary arteries was used to examine the role of active oxygen species in platelet aggregation in vivo. We studied 90 anesthetized dogs in which the pericardial cavity was opened and the heart was exposed. The velocity of blood flow in the left anterior descending coronary artery (LAD) was monitored by a pulsed Doppler flow probe. In 67 dogs, the LADs were stenosed by applying external constrictors at the site where the endothelium was mechanically injured. CFVs developed in all 67 dogs. Treatment with the antioxidants recombinant human copper-zinc superoxide dismutase (r-h-CuZnSOD), recombinant human manganese superoxide dismutase (r-h-MnSOD), and catalase eliminated platelet aggregation-associated coronary CFVs in 63%, 62%, and 64% of animals, respectively. Intravenous infusion of epinephrine restored CFVs in most dogs. Ketanserin, a serotonin (5-hydroxytryptamine2) receptor antagonist, abolished epinephrinerestored CFVs and eliminated CFVs in dogs in which CFVs had not been eliminated by free radical scavengers. In an additional 23 dogs, the LADs were stenosed but not mechanically injured. For control studies, saline was infused into the LADs of 5 dogs. Xanthine/xanthine oxidase was infused into the LADs of 8 dogs and induced CFVs in 4. Hydrogen peroxide was infused into the other 10 dogs and induced CFVs in 9. Histological analysis of the coronary artery revealed that the intima was significantly injured by the infusion. In ex vivo platelet aggregation studies, the in vivo treatment with r-h-CuZnSOD, r-h-MnSOD, and catalase significantly inhibited platelet aggregation induced by platelet-activating factor. Thus, active oxygen species are involved in mediating platelet aggregation and cyclic flow variations in stenosed and endothelium-injured canine coronary arteries in vivo. (Circ Res. 1993;73:952-967.) 
Under normal conditions, the accumulation of active oxygen species is limited by antioxidant enzymes and other nonenzymatic compounds. In the injured vessel, leukocyte infiltration into the vessel wall and platelet accumulation on the injured vascular surface could result in the production of excessive amounts of active oxygen species,12-14 which are highly reactive and potentially toxic. The arterial endothelium may also be a source of active oxygen species. Published data suggest that active oxygen species may alter endothelial function, influence vessel tone, and cause reperfusion injury of the myocardium. [15] [16] [17] In addition, active oxygen species may alter platelet aggregation in vitro. [18] [19] [20] [21] [22] [23] [24] [25] In the present study, we used an experimental canine model to test the hypothesis that active oxygen species are involved in mediating platelet aggregation in severely stenosed and endothelium-injured coronary arteries in vivo. Three antioxidant enzymes, recombinant human copper-zinc superoxide dismutase (r-h-CuZn-SOD), recombinant human manganese superoxide dismutase (r-h-MnSOD),2627 and catalase, were used to 
Measurements of r-h-CuZnSOD and r-h-MnSOD in the Circulation
The concentrations of r-h-CuZnSOD and r-h-Mn-SOD in the circulation of dogs in groups 1A and 2 were measured before and after treatment with each reagent. Blood was collected from the carotid arterial catheter and placed into serum separation tubes (Becton Dickinson Vacutainer System, Rutherford, NJ). Serum was separated and stored at -20°C until analyzed. Quantitation of the enzymes was performed by a radioimmunoassay with monoclonal antibodies to r-h-CuZnSOD and r-h-MnSOD. 35 (Table) . Heart rates and aortic pressures did not change significantly after the development of cyclic flow variations (Table) .
Effect of r-h-CuZnSOD, r-h-MnSOD, Catalase, and
Ketanserin on Spontaneous Cyclic Flow Variations
The administration of r-h-CuZnSOD at 2 mg/kg bolus and 0.8 mg/kg continuous infusion eliminated cyclic flow variations in 3 of the 7 dogs in group lA. Increasing the dose of r-h-CuZnSOD to a 6 mg/kg bolus and continuous infusion at 6 mg/(kg h) eliminated cyclic flow variations in 5 of 8 dogs in group lB. Cyclic flow variations were abolished in 8 of 13 dogs in group 2 by a 2 mg/kg bolus dose of r-h-MnSOD. This abolition rate was similar to that achieved by treatment with a high dose of r-h-CuZnSOD but slightly higher than that achieved by low-dose r-h-CuZnSOD treatment (Fig 2) . In group 3, catalase abolished cyclic flow variations in 7 of 11 dogs. These results are similar to those obtained with r-h-MnSOD. Ketanserin completely eliminated cyclic flow variations in those dogs in which cyclic flow variations were not abolished by initial treatment with r-h-CuZnSOD, r-h-MnSOD, or catalase. In group 4 dogs, ketanserin abolished cyclic flow variations in all 7 dogs (Fig 2) . Heart rates and aortic pressures were not significantly affected by treatment with r-h-CuZnSOD, r-h-MnSOD, catalase, or ketanserin (Table) . dogs in group 3 after their elimination by catalase, and in 6 of 7 dogs in group 4 after their elimination by ketanserin ( Fig 3A) . The frequency of epinephrine-restored cyclic flow variations was similar to that established initially (Table) . The severity of the restored cyclic flow variations (determined by nadir flow) was also the same as that observed in initial flow variations (Table) . The dose of epinephrine required to restore cyclic flow variations was slightly but not significantly higher in catalasetreated dogs than in other dogs (Fig 3B) .
Effect of the Combination of r-h-CuZnSOD, (Table) . However, the severity of the restored cyclic flow variations was much less than the severity of initial ones (Table) . The dose of epinephrine required to restore cyclic flow variations that had been eliminated by combination treatment was significantly higher than _e. that required to restore cyclic flow variations that had been abolished by single treatment (Fig 3B) .
Effects of Xanthine/Xanthine Oxidase and Hydrogen

Peroxide on Coronary Flow and Coronary Arterial Wall
In group 5 dogs, coronary arteries were stenosed by an external constrictor (Table) ; however, the endothe- lium was not injured with forceps. Infusion of saline into the coronary artery for 30 minutes did not significantly change coronary flow (Table) . Infusion of 4 ,ug xanthine and 4 mU xanthine oxidase per minute into the coronary arteries induced cyclic flow variations in 4 of 8 dogs. The xanthine/xanthine oxidase-induced cyclic flow variations were not persistent and faded immediately (Fig 4A) . Light and scanning electron microscopic examination of the coronary arteries revealed patches of endothelial cell loss or necrosis in the xanthine/ xanthine oxidase-infused segment (Fig 5A and SB) when compared with the normal left circumflex coronary artery in the same dog (Fig SC and 5D) . Cyclic flow variations never developed in the other 4 dogs, and ventricular fibrillation occurred after high doses of xanthine/xanthine oxidase were given.
Infusion of hydrogen peroxide into the coronary arteries induced persistent cyclic flow variations in 9 of 10 dogs (Fig 4B) . Hydrogen peroxide induced more frequent cyclic flow variations than did xanthine/xanthine oxidase (Fig 6) . Catalase was administered to 6 dogs with hydrogen peroxide-induced cyclic flow variations. Treatment with catalase abolished cyclic flow variations in 4 dogs (67%). Ketanserin eliminated the hydrogen peroxide-induced cyclic flow variations in the other 2 dogs. In the 4 dogs in whom catalase eliminated cyclic flow variations, discontinuation of catalase infusion restored cyclic flow variations with the same frequency and severity in approximately 30 minutes in all dogs (Fig 4C) . Ketanserin was then given to these animals, and it abolished the cyclic flow variations.
Examination of the coronary artery with light and scanning electron microscopy demonstrated a diminished endothelial circumference and marked fragmentation and separation of the media where hydrogen peroxide was infused (Fig 7A and 7B) . The left circumflex coronary artery from the same dog appeared normal (Fig 7C and 7D) . The 5 additional dogs (group 5C) into whose LADs saline was infused for 3 hours after placement of the constrictor did not develop cyclic flow variations. The constricted segment was examined with light microscopy; it revealed minor endothelial injury with intact internal elastic lamina in some areas and intact endothelium in other areas (Fig 8A and 8B) .
Relative Effects of r-h-MnSOD and Catalase on Cyclic Flow Variations
In group 6, initial treatment with r-h-MnSOD failed to eliminate cyclic flow variations in 5 of 10 dogs. The addition of catalase, however, completely abolished the remaining cyclic flow variations in those dogs (Fig 9) . Initial treatment with catalase did not eliminate cyclic flow variations in 5 of 11 dogs. Nor did the addition of r-h-MnSOD abolish the cyclic flow variations (Fig 9) .
The frequency of cyclic flow variations after the additional treatment with r-h-MnSOD was somewhat greater than the frequency after the initial treatment with catalase, although the difference was not statistically significant.
Circulating Concentrations of r-h-CuZnSOD and r-h-MnSOD
The concentrations of r-h-CuZnSOD and r-h-Mn-SOD in the peripheral blood were measured before and after their administration in dogs in groups 1A and 2. The concentrations of both r-h-CuZnSOD and r-hMnSOD peaked 10 minutes after administration; r-hCuZnSOD remained relatively constant for 3 hours, and r-h-MnSOD remained at a level higher than r-h-CuZn-SOD (Fig 10) . The concentration of r-h-MnSOD was approximately 3 times higher than that of r-h-CuZn-SOD after r-h-MnSOD was given as an intravenous bolus of 2 mg/kg and r-h-CuZnSOD was given as an intravenous bolus of 2 mg/kg and a continuous infusion at 0.8 mg/(kg h) (Fig 10) .
Effects of r-h-CuZnSOD, r-h-MnSOD, Catalase, and Ketanserin on Ex Vivo Platelet Aggregation
The ex vivo platelet aggregation induced by ADP, thromboxane mimetic U46619, or serotonin was not significantly changed by treatment with r-h-CuZnSOD, r-h-MnSOD, or catalase (Fig 11) . Platelet aggregation induced by platelet activating factor, however, was significantly inhibited by r-h-CuZnSOD, r-h-MnSOD, and catalase. Treatment with ketanserin inhibited serotonin-induced platelet aggregation but did not affect platelet aggregation induced by ADP, thromboxane mimetic, or platelet-activating factor.
Discussion
The present study demonstrates that administering the active oxygen species scavengers r-h-CuZnSOD, r-h-MnSOD, and catalase in vivo often eliminates platelet aggregation-associated cyclic flow reductions in severely stenosed and endothelium-injured canine coronary arteries.
Cyclic flow variations have been found to occur in the coronary arteries of some patients with unstable angina before and after coronary angioplasty. 37 The mechanisms involved in activation of platelets by active oxygen species are unclear. Previous studies have shown that aspirin and indomethacin have no effect on superoxide anion-induced platelet release reaction, which suggests that thromboxane is not involved in the activation of platelets by active oxygen species. 19 In the present study, r-h-CuZnSOD, r-h-MnSOD, and catalase significantly inhibited ex vivo platelet aggregation induced by platelet-activating factor but not by ADP, thromboxane mimetic, or serotonin. As shown in previous studies, platelet-activating factor is an important mediator of platelet aggregation and cyclic flow variations.40'4 Our data suggest that active oxygen species may affect the activation of platelets by platelet-activating factor.
Mehta et a142 and other investigators43-46 have reported that production of active oxygen species during reperfusion of the ischemic myocardium causes vessel dysfunction and that superoxide dismutase protects the vasodilator ability of the vessel. Gryglewski et a147 reported that superoxide anions are involved in the breakdown of endothelium-derived relaxing factor. Mugge et a148 found that the release of intact endothelium-derived relaxing factor depends on endothelial superoxide dismutase activity. It also has been demonstrated that CuZnSOD enhances vasodilation in human coronary arteries mediated by endothelium-derived relaxing factor (personal communication, Dr Amnon Gonenne, BioTechnology, New York, NY). Studies from our laboratory indicate that endogenously produced endotheliumderived relaxing factor protects against platelet aggregation and cyclic flow variations. 49 These findings suggest that active oxygen species may mediate cyclic flow variations by reducing the effect of endotheliumderived relaxing factor.
The effect of hydrogen peroxide on endotheliumderived relaxing factor is controversial. Kontos et a150 found that application of hydrogen peroxide to the surface of cat brain inhibits vasodilation mediated by endothelium-derived relaxing factor. Marczin et al34 discovered that treating calf pulmonary artery endothelial cells with hydrogen peroxide reduces the production of endothelium-derived relaxing factor. Burke-Wolin et al,51 however, demonstrated that hydrogen peroxide enhances the effect of endothelium-derived relaxing factor by activating guanylate cyclase, which results in the accumulation of cGMP. The effect of hydrogen peroxide on endothelium-derived relaxing factor and the contribution of hydrogen peroxide to cyclic flow variations in this model need further investigation.
Active oxygen species may alter human vascular endothelial cell function and may increase platelet adherence to endothelial cells.15 Hladovec52 reported that active oxygen species may cause endothelemia in the rat. Poelstra et al53 demonstrated that active oxygen species can impair the vascular activity of ADPase. Our previous studies have shown that ADPase may prevent platelet aggregation and cyclic flow variations.31 Together, these data suggest that free radicals may contribute to the development of cyclic flow variations by damaging endothelial cells. We have provided further evidence of endothelial injury caused by active oxygen species in our scanning electron micrographs of coronary arteries exposed to xanthine/xanthine oxidase and Epinephrine is present in the circulation but usually not in levels sufficiently high to activate platelets. 54 In some situations, however, the concentration of epinephrine in the circulation increases dramatically. This increase could induce platelet aggregation even when the concentration of other platelet agonists is very low.55 Studies from our laboratory have revealed that, at certain doses, epinephrine was able to restore cyclic flow variations that had been eliminated by antagonists to certain platelet receptors, thromboxane, serotonin, and ADP. 31, 33, 56 In the present study, epinephrine restored cyclic flow variations in most dogs treated singly with r-h-CuZnSOD, r-h-MnSOD, and catalase in a dose range similar to that in dogs treated with a single antagonist of ADP, thromboxane, and serotonin.3"33"56
Epinephrine restored cyclic flow variations in fewer dogs when the serotonin receptor antagonist, ketanserin, was added to the regimen. The dose of epinephrine required to restore cyclic flow variations was significantly higher in animals treated with the combination of ketanserin and active oxygen species scavengers than those treated with a single agent. These data suggest that, together, eliminating active oxygen species and blocking platelet receptors to serotonin with ketanserin may protect against the restoration of cyclic flow variations induced by epinephrine. Active oxygen species may have an additive effect with other platelet-derived factors on the activation of platelets. Protection against epinephrine-restored cyclic flow variation was slightly better in animals treated with a combination of r-hMnSOD and ketanserin than in those treated with r-h-CuZnSOD and ketanserin, perhaps because r-hMnSOD has a longer half-life in the circulation than r-h-CuZnSOD.57,58
In conclusion, active oxygen species may contribute to platelet aggregation and cyclic flow variations in severely stenosed and endothelium-injured canine coronary arteries through several different mechanisms. Eliminating active oxygen species in the circulation may prevent cyclic flow variations. Furthermore, eliminating active oxygen species and blocking platelet receptors to serotonin may protect against epinephrine-induced cyclic flow variations.
